Open Access

REVIEW

Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma

Gokhan Koc¹, Xu Wang², Yi Luo³

1 Department of Urology, Tepecik Teaching and Research Hospital, Yenisehir, Izmir, Turkey
2 Tianjin Institute of Urology, Tianjin Medical University, Tianjin, China
3 Department of Urology, University of Iowa, Iowa City, Iowa USA
Address correspondence to Dr. Yi Luo, Department of Urology, University of Iowa, 375 Newton Road, 3204 MERF, Iowa City, IA 52242 USA

Canadian Journal of Urology 2011, 18(6), 5991-5997.

Abstract

Introduction: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for approximately 90% of all kidney cancers. Prior to 2005, treatment options for patients with locally advanced and metastatic disease were limited. After the approval of sorafenib by the US Food and Drug Administration (FDA), other tyrosine kinase inhibitors (TKI) have been successively used for treating patients with advanced RCC. Pazopanib is the newest, orally bioavailable, and multi-targeted TKI, and is considered a first-line treatment option for certain patients. This review summarizes updated clinical studies, mechanism of action, and pharmacokinetics of pazopanib.
Materials and methods: Published English language literatures and data information on pazopanib for treating advanced RCC available as of March 2011 were identified and summarized.
Results: In phase II and III randomized clinical trials, pazopanib treatment resulted in considerably longer progression-free survival in patients with advanced RCC compared to placebo, with an acceptable side-effect profile. In addition, there are a few ongoing pazopanib studies including comparison to other TKIs, use for patients who have failed prior cytokine therapy, and combination with other therapeutic agents.
Conclusions: Pazopanib has been used in the United States, Europe and Canada for treating patients with advanced RCC. Currently, it is being used in good or intermediate risk RCC and shows survival benefit with acceptable adverse effects. Pazopanib is a new treatment option and needs further evaluation, particularly on its effect relative to other TKIs as well as its use in combination with other agents.

---

Keywords

---